|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Respiratory Diseases, University Hospital, Ghent, Belgium.
Correspondence to: Romain Pauwels, MD, FCCP, Department of Respiratory Diseases, University Hospital, De Pintelaan 185, B9000 Ghent, Belgium; e-mail: email:romain.pauwels{at}rug.ac.be
In 1995, the European Respiratory Society published a European Consensus Statement on the optimal assessment and management of COPD. In the document, several important areas for future research are identified that may help to increase knowledge of the current situation of COPD within Europe; these include pathophysiology, epidemiology, and the clinical benefits of treatment. This article reviews a selection of important data that have become available since the consensus statement was published, with a specific focus on epidemiology and treatment.
Key Words: COPD epidemiology prevalence treatment
This article has been cited by other articles:
![]() |
O. Leclerc, V. Lagente, J-M. Planquois, C. Berthelier, M. Artola, T. Eichholtz, C. P. Bertrand, and F. Schmidlin Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice Eur. Respir. J., June 1, 2006; 27(6): 1102 - 1109. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |